A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies

Phase 1 Study Of Sunitinib (SU011248) In Combination With Pemetrexed In Patients With Advanced Solid Malignancies In Japan

This study will assess if the combination of sunitinib and pemetrexed is tolerable when coadministered at each recommended dose/schedule.

Inclusion Criteria:

• Patients with a diagnosis of a solid malignancy that is refractory to standard therapy or for which no standard therapy exists.
• Patients has a good performance status (ECOG 0 or 1)

Exclusion Criteria:

• Prior treatment with either pemetrexed or SU011248.
• Coughing up blood within 4 weeks before starting study treatment (small amounts okey).
• Hypertension that cannot be controlled by medications.